Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04059523 · ClinicalTrials.gov registry record · Phase 1
MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3
A Phase 1 study, sponsored by Sol-Gel Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT04059523 is a Phase 1 study that has completed, run by Sol-Gel Technologies. The registered enrollment target is 62 participants.
The verdict
NCT04059523, a Phase 1 study, has completed, sponsored by Sol-Gel Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
To assess the degree of systemic exposure of S6G5T-3 compared to the Reference Listed Drug (RLD) Retin-A® 0.1% Cream when applied topically once daily for 14 days, under maximal use conditions in adolescents ≥12 years of age and adults with acne vulgaris.
Interventions
- DRUG S6G5T-3
- DRUG Retin-A® 0.1% Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2019-06-27 |
| Est. Completion | 2020-02-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04059523
The ClinicalTrials.gov registry entry for NCT04059523 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sol-Gel Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which S6G5T-3 is the first listed.
NCT04059523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04059523 about?
NCT04059523 is a clinical study titled "MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3". To assess the degree of systemic exposure of S6G5T-3 compared to the Reference Listed Drug (RLD) Retin-A® 0.1% Cream when applied topically once daily for 14 days, under maximal use conditions in adolescents ≥12 years of age and adults with acne vulgaris.
What is the current status of trial NCT04059523?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2019-06-27. Estimated completion is 2020-02-06.
What interventions are being tested in trial NCT04059523?
The interventions under investigation include: S6G5T-3 (DRUG), Retin-A® 0.1% Cream (DRUG).
Who is sponsoring clinical trial NCT04059523?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.